Screener / SEC EDGAR /CIK 0001237831 /10-K filed Feb 24, 2026, compared with Feb 20, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Medical Instruments

Globus Medical Inc GMED

Compare with peers Embed
The 10-K against last year's

114 changes: 18 added, 21 removed, 72 reworded, 3 quiet changes

10-K Feb 24, 2026 vs Feb 20, 2025

10-K 0001628280-26-011209 (Feb 24, 2026) vs 10-K 0001562762-25-000026 (Feb 20, 2025)

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

315 paragraphs · 9 new · 182 reworded · 12 gone · 10-K Feb 24, 2026 against Feb 20, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 148 · 49% changed Every version of it
The proliferation •recalls or seizures of physician-owned distributorships (“PODs”) could result in increased pricing pressure on our products or harm limits on our ability to sell our products to physicians. in certain territories;
Paragraph 173 · 46% changed Every version of it
In the U.S., the procurement and transplantation of allograft bone tissue is subject to federal law pursuant to the NOTA, a criminal statute which prohibits the purchase and sale of human organs used in human transplantation, including bone and related tissue, for “valuable consideration.” NOTA permits reasonable payments associated with the removal, transportation, processing, preservation, quality control, implantation and storage of human bone tissue. We provide services in all of these areas in the U.S., with the exception of removal and implantation, and receive payments for all such services. We make payments to tissue banks for their services related to recovering allograft bone tissue on our behalf. If NOTA is interpreted or enforced in a manner that prevents us from receiving payment for services we render or that prevents us from paying tissue banks or certain of our clients for the services they render for us, our business could be materially adversely affected. In addition, there is similar legislation in Europe and the UK which we must abide by, including Directive 2004/23/EC in relation to human tissues and cells requiring that donation be unpaid (except for expenses and inconvenience) and voluntary.
Paragraph 137 · 46% changed Every version of it
The processes by which 510(k) clearance, grant of a de novo classification request, or PMA approval is obtained can be expensive and lengthy and require the payment of significant fees. The FDA’s 510(k) clearance process usually takes from three to twelve months, but may last longer. The FDA’s goal is to review de novo classification requests within 150 FDA review days, but presently, the current average review period is about eight months. The process of obtaining a PMA is much costlier and more uncertain than the 510(k) clearance process and generally takes one to three years, or even longer, from the time the application is submitted to the FDA until an approval is obtained. The process of obtaining regulatory clearances through the 510(k) process, de novo classification, or approvals through the PMA process to market a medical device in the U.S. or internationally can be costly and time-consuming, and we may not be able to obtain these clearances, grants of de novo classification, or approvals on a timely basis, if at all.
Paragraph 92 · 44% changed Every version of it
Our business could suffer if we lose the services of key members of our senior management, key advisors or personnel. personnel, and if we do not successfully manage the transition associated with the resignation of our former chief executive officer and the appointment of our new chief executive officer, it could have an adverse impact on our business.
Paragraph 292 · 43% changed Every version of it
We could be negatively affected by the widespread outbreak of a communicable disease, or any other public health crisis that results in disruptions to hospitals and other healthcare facilities. The preventative and precautionary measures that hospitals and federal, state, local, and international governments can take to mitigate the spread of diseases lead to restrictions on, disruptions in, and other related impacts on elective procedure rates. This could cause delays and component shortages that could impact our ability to manufacture our products by extending our lead times. These disruptions may impact our ability to satisfy customer demand, which could negatively impact our results of operations.
Paragraph 182 · 41% changed Every version of it
There are numerous U.S. federal and state laws pertaining to healthcare fraud and abuse, including anti-kickback laws, false claims laws and physician self-referral laws. Our relationships with surgeons, hospitals and our independent distributors are subject to scrutiny under these laws. Violations of these laws are punishable by criminal and civil sanctions, including, in some instances, imprisonment and exclusion from participation in federal and state healthcare programs, including the Medicare, Medicaid and Veterans Administration health programs. Because of the broad and far-reaching nature of these laws, we may be required to alter or discontinue one or more of our business practices.
Paragraph 243 · 39% changed Every version of it
Our existing revolving credit facility contains certain restrictive covenants that could limit our ability to transfer or dispose of assets, merge with other companies or consummate certain changes of control, acquire other companies, pay dividends, incur additional indebtedness and liens, experience changes in management and enter into new businesses. We therefore may not be able to engage in any of the foregoing transactions unless we obtain the consent of the lender or terminate the revolving credit facility. There is no guarantee that we will be able to generate sufficient cash flow or sales to meet the financial covenants or pay the principal and interest on any such debt. Furthermore, there is no guarantee that future working capital, borrowings or equity financing will be available to repay or refinance any such debt.
Paragraph 88 · 34% changed Every version of it
We generally use a small number of suppliers for our products, materials and components. Our dependence on such a limited number of suppliers exposes us to risks, including limited control over pricing, availability, quality and delivery schedules. Our suppliers may be impacted by equipment failure or economic, environmental, or geopolitical factors that disrupt manufacturing capacities. If any one or more of our suppliers cease to provide us with sufficient quantities of products or materials in a timely manner or on terms acceptable to us, or cease to manufacture components of acceptable quality, we would have to seek alternative sources of supply. Because of the nature of our internal quality control requirements, regulatory requirements and the custom and proprietary nature of components, we cannot quickly engage additional or replacement suppliers for many of our critical components. Failure of any of our third-party suppliers to deliver products or materials at the level our business requires would limit our ability to meet our sales commitments to our customers and could have a material adverse effect on our business. We may also have difficulty obtaining similar components from other suppliers that are acceptable to the FDA or other foreign regulatory authorities. We could incur delays while we locate and engage qualified alternative suppliers, and we may be unable to engage alternative suppliers on favorable terms or at all. We cannot guarantee that disruptions will not occur, and any such disruption may result in decreased inventory, increased overhead costs, product shortages and decreased sales, any of which could have a material adverse effect on our business, results of operations and financial condition, and could harm our commercialization efforts and adversely affect our ability to generate future sales.

MD&A

86 paragraphs · 9 new · 46 reworded · 9 gone · 10-K Feb 24, 2026 against Feb 20, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 48 · 50% changed
We estimate the fair value of stock options utilizing the Black-Scholes option-pricing model. Inputs to the Black-Scholes model include our stock price, expected volatility, expected term, risk-free interest rate and expected dividends. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period commensurate with the estimated expected term of the Company’s stock options offering period which is derived from historical experience. The risk-free interest rate assumption is based on observed interest rates of U.S. Treasury securities appropriate for the expected terms of the stock options. The dividend yield assumption is based on the history and expectation of no dividend payouts. The fair value of restricted stock units RSUs is estimated on the day of grant based on the closing price of the Company’s Class A common stock.
Paragraph 73 · 49% changed
The decrease increase of $77.5 million $52.8 million, or 116.7%, in other income/(expense), was primarily due to $43.3 a $3.0 million of foreign currency loss and increases in interest expense of $29.4 million from amortization of the fair value adjustment on the 2025 Notes from acquisition accounting and other contractual interest incurred. Additionally, interest income decreased by $8.2 million which was driven by a lower average marketable securities portfolio size and lower market-related yields in the current period compared to a $43.2 million loss in the prior period. Additionally, there was a $19.5 million decrease in
Paragraph 26 · 49% changed
The preparation of the consolidated financial statements requires us to make assumptions, estimates and judgments that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities as of the date of the consolidated financial statements, and the reported amounts of sales and expenses during the reporting periods. Certain of our more critical accounting policies require the application of significant judgment by management in selecting the appropriate assumptions for calculating financial estimates. By their nature, these judgments are subject to an inherent degree of uncertainty. On an ongoing basis, we evaluate our judgments, including but not limited to those related to inventories, recoverability of long-lived assets and the fair value of our common stock. We use historical experience and other assumptions as the basis for our judgments and making these estimates. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any changes in those estimates will be reflected in our consolidated financial statements as they occur. While our significant accounting policies are more fully described in “Part II; Item 8. Financial Statements and Supplementary Data; Notes to Consolidated Financial Statements; Note 2. Summary of Significant Accounting Policies” below in this Annual Report, we believe that the following accounting policies and estimates are most critical to a full understanding and evaluation of our reported financial results. The critical accounting policies addressed below reflect our most significant judgments and estimates used in the preparation of our consolidated financial statements. We have reviewed these critical accounting policies with the audit committee of our Board.
Paragraph 59 · 43% changed
The $487.3 million $77.7 million, or 88.9% increase 7.5%, decrease in cost of sales for the year ended December 31, 2025 was primarily driven by increases to inventory product costs of $221.0 million from increased volume, significantly due to the NuVasive Merger. Additionally, there was increased amortization of inventory fair value step-up of $143.8 million, due to a full year of post-acquisition amortization occurring in $215.4 million included within the current period December 31, 2024 balance as compared to four months in the prior period. Further, increases in costs Nevro amortization of inventory fair value step-up of $19.3 million included within the year ended December 31, 2025. This was partially offset by an increase due to the cost of sales were also impacted by from Nevro products of $91.2 million, and an increase in depreciation of $29.2 million and increased changes in excess and obsolete inventory reserves by $12.4 $18.3 million.
Paragraph 65 · 40% changed
Amortization of intangibles increased decreased by $68.3 million $1.2 million, or 133.9% 1.0%, for the year ended December 31, 2024 2025 compared to the year ended December 31, 2023, due to the impact of the intangibles acquired from the NuVasive Merger. They contributed $103.1 million in amortization expense in the current period as compared to $34.1 million in amortization expense for the year ended December 31, 2023. 2024.
Paragraph 5 · 40% changed
On September 1, 2023, April 3, 2025, pursuant to the terms of that certain merger agreement (the “Merger “Nevro Merger Agreement”) with NuVasive, Inc. (“NuVasive”) Nevro Corp. (“Nevro”) and Zebra Merger Sub Inc. (“Merger Sub”), Palmer Merger Sub, Inc., a wholly owned subsidiary of the Company, Company (“Palmer Merger Sub”), Palmer Merger Sub merged with and into NuVasive, Nevro (the “Nevro Merger” and, together with the NuVasive Merger, the “NuVasive and Nevro Mergers”), with Nevro surviving as a wholly owned subsidiary of the Company (the “NuVasive Merger”). Under Company. Upon the Merger Agreement, consummation of the Nevro Merger, each issued and outstanding share of common stock, stock of Nevro, $0.001 par value $0.001 per share, of NuVasive issued and outstanding immediately prior to the effective time (other than certain excluded shares as described in the Merger Agreement) was cancelled and converted into the right to receive 0.75 fully paid and non-assessable shares of Class A Common of Globus, $0.001 par value per share, and the right to receive cash in lieu an amount equal to $5.85 per share of fractional shares. common stock of Nevro, without interest and subject to any applicable withholding taxes.
Paragraph 17 · 39% changed
While we have increased our in-house implant product manufacturing capacity and assemble our INR systems in-house, we also have products manufactured by third-party suppliers. Substantially all of our suppliers manufacture our products in the U.S. Our cost of sales consists primarily of costs from our in-house manufacturing, costs of products purchased from third-party suppliers, excess and obsolete inventory charges, depreciation of surgical instruments and cases, royalties, shipping, inspection and related costs incurred in making our products available for sale or use.
Paragraph 84 · 37% changed
The higher cash used in investing activities for the year ended December 31, 2024 2025 was primarily due primarily to decreases an increased outflow of $234.9 million in marketable securities net inflows acquisition of $720.3 million as we manage our liquidity, as well as increased businesses and an increase in purchases of property and equipment of $37.2 million primarily driven by increased production resulting from the NuVasive Merger. These were $49.3 million, partially offset by decreased outflows for the acquisition increased sales of businesses, net marketable securities of cash acquired of $278.4 million, with individually immaterial acquisitions occurring in the current period as compared to the prior period that was primarily driven by the NuVasive Merger. $103.8 million.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

MD&A192 words changed in this paragraph; it is 43% similar to last year's version.
The preparation of the consolidated financial statements requires us to make assumptions, estimates and judgments that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities as of the date of the consolidated financial statements, and the reported amounts of sales and expenses during the reporting periods. Certain of our more critical accounting policies require the application of significant judgment by management in selecting the appropriate assumptions for calculating financial estimates. By their nature, these judgments are subject to an inherent degree of uncertainty. On an ongoing basis, we evaluate our judgments, including but not limited to those related to inventories, recoverability of long-lived assets and the fair value of our common stock. We use historical experience and other assumptions as the basis for our judgments and making these estimates. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any changes in those estimates will be reflected in our consolidated financial statements as they occur. While our significant accounting policies are more fully described in “Part II; Item 8. Financial Statements and Supplementary Data; Notes to Consolidated Financial Statements; Note 2. Summary of Significant Accounting Policies” below in this Annual Report, we believe that the following accounting policies and estimates are most critical to a full understanding and evaluation of our reported financial results. The critical accounting policies addressed below reflect our most significant judgments and estimates used in the preparation of our consolidated financial statements. We have reviewed these critical accounting policies with the audit committee of our Board.

Source: Item 7, 10-K 0001628280-26-011209 vs Item 7, 10-K 0001562762-25-000026

Accounting Policies148 words changed in this paragraph; it is 40% similar to last year's version.
In December 2023, July 2025, the FASB issued ASU No. 2023-09, Income Taxes 2025-05, Financial Instruments—Credit Losses (Topic 740), Improvements 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. ASU No. 2025‑05 provides a practical expedient that allows entities to Income Tax Disclosures, estimate expected credit losses on certain trade receivables and contract assets by assuming that current economic conditions will remain unchanged over the life of the asset. The expedient applies only to enhance the transparency and decision-making utility assets with contractual lives of income tax disclosures. The enhancement will provide information to better assess how an entity’s operations and related tax risks and tax planning and operational opportunities affect its tax rate and prospects for future cash flows. Investors currently rely on the rate reconciliation table and other disclosures, including total income taxes paid, to evaluate income tax risks and opportunities. This update one year or less. ASU No. 2025‑05 is effective for fiscal years beginning after December 15, 2024. Early 2025, and early adoption is permitted. The amendments should be applied prospectively with retrospective applications also permitted. prospectively. The Company is currently evaluating the impact the standard will have on its consolidated financial statements and related disclosures.

Source: Item 8, Note 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, 10-K 0001628280-26-011209 vs Item 8, Note 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, 10-K 0001562762-25-000026

Risk Factors101 words changed in this paragraph; it is 78% similar to last year's version.
We generally use a small number of suppliers for our products, materials and components. Our dependence on such a limited number of suppliers exposes us to risks, including limited control over pricing, availability, quality and delivery schedules. Our suppliers may be impacted by equipment failure or economic, environmental, or geopolitical factors that disrupt manufacturing capacities. If any one or more of our suppliers cease to provide us with sufficient quantities of products or materials in a timely manner or on terms acceptable to us, or cease to manufacture components of acceptable quality, we would have to seek alternative sources of supply. Because of the nature of our internal quality control requirements, regulatory requirements and the custom and proprietary nature of components, we cannot quickly engage additional or replacement suppliers for many of our critical components. Failure of any of our third-party suppliers to deliver products or materials at the level our business requires would limit our ability to meet our sales commitments to our customers and could have a material adverse effect on our business. We may also have difficulty obtaining similar components from other suppliers that are acceptable to the FDA or other foreign regulatory authorities. We could incur delays while we locate and engage qualified alternative suppliers, and we may be unable to engage alternative suppliers on favorable terms or at all. We cannot guarantee that disruptions will not occur, and any such disruption may result in decreased inventory, increased overhead costs, product shortages and decreased sales, any of which could have a material adverse effect on our business, results of operations and financial condition, and could harm our commercialization efforts and adversely affect our ability to generate future sales.

Source: Item 1A, 10-K 0001628280-26-011209 vs Item 1A, 10-K 0001562762-25-000026

Legal Proceedings3 words changed in this paragraph; it is 99% similar to last year's version.
On November 20, 2019, Moskowitz Family LLC (“Moskowitz”) filed suit against us in the U.S. District Court for the Western District of Texas for patent infringement. Moskowitz, a non-practicing entity, alleges that Globus willfully infringes one or more claims of six patents by making, using, offering for sale or selling the COALITION MIS®, CORBEL®, MAGNIFY®-S, HEDRON IATM, INDEPENDENCE MIS®, INDEPENDENCE MIS AGX®, FORTIFY® and XPAND® families, SABLE®, RISE®, RISE® INTRALIF, RISE®-L, ELSA®, ELSA® ATP, ALTERA®, ARIEL®, CALIBER® and CALIBER®-L products. Moskowitz seeks monetary damages and injunctive relief. On July 2, 2020, this suit was transferred from the U.S. District Court for the Western District of Texas to the U.S. District Court for the Eastern District of Pennsylvania. On December 14, 2023, a jury returned a defense verdict in favor of Globus. On September 30, 2024, Moskowitz Family LLC filed an appeal to the verdict. The outcome of this litigation cannot be determined, nor can we estimate a range of potential loss, therefore, we have not recorded a liability, outside of counsel fees, related to this litigation as of December 31, 2024. 2025.

Source: Item 3, via Note 15 – COMMITMENTS AND CONTINGENCIES, 10-K 0001628280-26-011209 vs Item 3, via Note 15 – COMMITMENTS AND CONTINGENCIES, 10-K 0001562762-25-000026

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of GMED's Risk Factors and MD&A, 10-K Feb 24, 2026 against 10-K Feb 20, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
Additionally, during 2025, Daniel Scavilla, our former Chief Executive Officer, resigned from the Company and was replaced by Mr. Pfeil, who had previously served as the Chief Operating Officer and Chief Financial Officer. Although the Board is confident in the leadership of Mr. Pfeil, leadership transitions can be inherently difficult to manage, and an inadequate transition may cause disruption to the Company’s business. Accordingly, if we do not successfully manage the transition, it could have an adverse impact on our business.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
In 2025, the U.S. enacted the imposition of widespread and substantial tariffs on imports, which resulted in the imposition of reciprocal or retaliatory tariffs and continued tariff volatility and uncertainty. The tariffs enacted by the U.S. included a universal
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
baseline tariff of 10%, plus an additional country-specific tariff for select countries. On February 20, 2026, the U.S. Supreme Court held that the U.S. administration’s imposition of many such tariffs was unlawful, striking down the 10% tariff, as well as the higher tariffs imposed on certain U.S. partners, including, among others, Canada, Mexico, and China. The U.S. Supreme Court’s ruling did not affect all of the recently imposed tariffs. Nor does it prohibit the imposition of future tariffs through alternative trade authorities available to the U.S. administration. Accordingly, uncertainty with respect to the tariffs remains ongoing, and we are unable to predict what additional actions, if any, may ultimately be taken by the U.S. or other governments with respect to tariffs or trade relations, which products may be subject to such actions (including subject to U.S. export control restrictions), or what actions may be taken by any other countries in retaliation, or the impact, if any, that any such policy changes could have on our business. The potential resultant impact of the imposition of these or any other new or increased tariffs on import markets has and could further have an adverse effect on Globus’ results of operations, cash flow and financial condition.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
unsafe condition or injury to patients. The medical devices industry has been particularly prone to potential product liability claims that are inherent in the testing, manufacture and sale of medical devices and products for surgery procedures.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
are no longer a controlled company, you will not have the same protections afforded to stockholders of companies that are subject to all of the New York Stock Exchange’s corporate governance requirements.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
The Company’s Bylaws provide, to the fullest extent permitted by law, that the Court of Chancery of the State of Delaware will be the exclusive forum for certain legal actions between the Company and its stockholders, which could increase costs to bring a claim, discourage claims or limit the ability of the Company’s stockholders to bring a claim in a judicial forum viewed by the stockholders as more favorable for disputes with the Company or the Company’s directors, officers or other employees.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
Our Bylaws provide, to the fullest extent permitted by law, that unless the Company consents in writing to the selection of an alternative forum, the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the Company; (ii) any action asserting a claim of breach of a fiduciary duty owed by any director or officer or other employee of the Company to the Company or the Company’s stockholders; (iii) any action asserting a claim against the corporation or any director or officer or other employee of the Company arising pursuant to any provision of the General Corporation Law of Delaware or the certificate of incorporation or the Bylaws (as either may be amended from time to time); and (iv) any action asserting a claim against the Company or any director or officer or other employee of the Company governed by the internal affairs doctrine, in each case, shall be the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court of the District of Delaware).
Read it in 10-K Feb 24, 2026 at sec.gov
Show the other 58
AddedRisk Factors
Additionally, our Bylaws provide that unless the Company consents in writing to the selection of an alternative forum, the federal district courts of the U.S. shall be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. The choice of forum provisions may increase costs to bring a claim, discourage claims or limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with the Company or the Company’s directors, officers or other employees, which may discourage such lawsuits against the Company or the Company’s directors, officers and other employees. Alternatively, if a court were to find the choice-of-forum provisions contained in the Bylaws to be inapplicable or unenforceable in an action, the Company may incur additional costs associated with resolving such action in other jurisdictions. The exclusive forum provisions in the Bylaws will not preclude or contract the scope of exclusive federal or concurrent jurisdiction for actions brought under the federal securities laws including the Exchange Act or the Securities Act, as amended, or the respective rules and regulations promulgated thereunder.
Read it in 10-K Feb 24, 2026 at sec.gov
RemovedRisk Factors
The Company expects to incur substantial expenses related to the integration of NuVasive and may be unable to realize the anticipated synergies, which could adversely affect the Company’s business, financial condition and results of operations.
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedRisk Factors
We depend on a limited number of sources of human tissue for use in some of our regenerative biologics products and a limited number of entities to process the human tissue for use in those regenerative biologics products, and any failure to obtain tissue from
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedRisk Factors
As of December 31, 2024, we had outstanding $450.0 million aggregate principal amount of our 0.375% Convertible Senior Notes due March 15, 2025, (the “2025 Notes”). This significant amount of debt has important risks to us and our investors, including:
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedRisk Factors
Our rapid growth has placed, and will continue to place, a significant strain on our management and on our operational and financial resources and systems. Failure to manage our growth effectively could cause us to over-invest or under-invest in infrastructure, and result in losses or weaknesses in our infrastructure, which could materially adversely affect us. Additionally, our anticipated growth will increase the demands placed on our suppliers, resulting in an increased need for us to carefully monitor for quality assurance. Any failure by us to manage our growth effectively could have an adverse effect on our ability to achieve our development and commercialization goals.
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedRisk Factors
On February 1, 2025, President Trump announced the imposition of additional substantial tariffs on imports from various countries, including China, Canada and Mexico, and the subject countries indicated their intention to impose counter measures. Under the announced measures, a 25% tariff will be applied to steel and aluminum products from Canada and Mexico, while a 10% tariff will be imposed on steel and aluminum imports from China.
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedRisk Factors
The Company expects to incur substantial expenses related to the integration of NuVasive and may be unable to realize the anticipated synergies, which could adversely affect the Company’s business, financial condition and results of operations.
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedRisk Factors
As a result of the NuVasive Merger, the Company may experience impacts on relationships with contractual counterparties (such as business partners, surgeons, vendors, sales representatives, contractors, distributors or other third-party service providers) that may harm the Company’s business and results of operations. Certain counterparties may seek to terminate or modify contractual obligations following the NuVasive Merger whether or not contractual rights are triggered as a result of the NuVasive Merger. There can be no guarantee that Globus’s or NuVasive’s contractual counterparties will remain with or continue to have a relationship with the Company or do so on the same or similar contractual terms following the NuVasive Merger. If any contractual counterparties (such as business partners, surgeons, vendors, sales representatives, contractors, distributors or other third-party service providers) seek to terminate or modify contractual obligations or discontinue their respective relationships with the Company, then the Company’s business and results of operations may be harmed.
Read it in 10-K Feb 20, 2025 at sec.gov
RewordedRisk Factors
Our business could suffer if we lose the services of key members of our senior management, key advisors or personnel. personnel, and if we do not successfully manage the transition associated with the resignation of our former chief executive officer and the appointment of our new chief executive officer, it could have an adverse impact on our business.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
Accordingly, while we remain a controlled company and during any transition period following a time when we are no longer a controlled company, you will not have the same protections afforded to stockholders of companies that are subject to all of the New York Stock Exchange’s corporate governance requirements.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
A determination that we have failed to comply, whether knowingly or inadvertently, may result in substantial penalties, including fines and enforcement actions and civil and/or criminal sanctions, the disgorgement of profits and the imposition of a court-appointed monitor, as well as the denial of export privileges, and may have an adverse effect on our reputation.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
Reimbursement and healthcare payment systems in international markets vary significantly by country, and include both government-sponsored healthcare and private insurance. insurance and generally have lower prices and more restrictive reimbursement conditions than in the U.S.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
If implemented, these Specifically, changes to tariffs and countermeasures trade policies have and could increase continue to impact the cost of raw materials and components necessary for our operations, disrupt our global supply chain and create additional operational challenges.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
The Patent litigation is highly prevalent in the medical device industry is characterized by patent litigation industry, and we could become subject to litigation that could be costly, result in the diversion of management’s time and efforts, require us to pay damages, and/or prevent us from marketing our existing or future products.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
From time to time we We have acquired, and expect to consider opportunities in the future to acquire or make investments in other in, technologies, products and businesses that may enhance our capabilities, complement our current products or expand the breadth of our markets or customer base.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
We operate in a very competitive business environment and if we are unable to compete successfully against our existing or potential competitors, our sales sales, operating results, and operating results growth may be negatively affected and we may not grow. affected.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
The techniques used by criminal elements to attack computer systems are sophisticated, change frequently and may originate from less regulated and remote areas of the world, including countries that engage in state-sponsored cyber attacks.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
Shifts As discussed in greater detail below, shifts in governmental policies including tariffs, trade policies or regulations in various jurisdictions have and could continue to increase the cost of raw materials and components necessary for our operations, disrupt supply chains and negatively impact profitability.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
Integrating the NuVasive business acquired businesses into Globus may be more difficult, costly or time-consuming than expected and the Company may fail to realize the anticipated benefits of the NuVasive Merger, such acquisitions, which may adversely affect the Company’s business results and negatively affect the value of the Company’s Class A common stock.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
EU CE markings for medical devices will continue to be recognized in Great Britain until June 30, 2028, and certificates issued for medical devices by EU-recognized EU-designated Notified Bodies will continue to be valid for the Great Britain market until June 30, 2028 and 2028; however the EU no longer recognizes UK Notified Bodies, now known as Approved Bodies.
Read it in 10-K Feb 24, 2026 at sec.gov
Quiet changesRisk Factors
As a result, we currently lack the breadth of published long-term clinical data supporting the safety and efficacy of virtually all many of our products and the benefits they offer that might have been generated in connection with other approval processes.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
treat chronic pain. Our neuromonitoring services use proprietary software-driven nerve detection and avoidance technology and include intraoperative neuromonitoring (“IONM”) services to aid spine surgery.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
Restructuring costs represent costs associated with the Company’s plans to optimize the organizational structure, merge synergies and leverage the strength of both commercial organizations.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
The $16.5 million, or 10.1%, decrease in research and development expenses for the year ended December 31, 2025 was primarily driven by a decrease of $21.9 million in employee-related expenses, excluding Nevro employee-related expenses, and a decrease of $12.6 million in acquired intellectual property research and development. This decrease was partially offset by an increase of $15.2 million for Nevro research and development expenses.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
The increase of $197.1 million, or 20.1%, in selling, general and administrative expenses for the year ended December 31, 2025 was primarily driven by an increase of $160.2 million for Nevro expenses. Additionally, there was an increase of $37.4 million in provision for litigation driven by the accrual of $43.1 million in the third quarter of the year ended December 31, 2025 related to the Pimenta Litigation (as defined in Note 15, Commitments and Contingencies in “Item 8. Financial Statements and Supplementary Data”) offset by $5.7 million of various net settlements received.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
The decrease in restructuring costs of $8.7 million compared to the same period of the prior year was primarily due to lower employee termination benefit expenses from the 2024 Synergy Plan and the 2025 Strategic Integration Plan (each as defined in Note 16, Restructuring And Other Costs in “Item 8. Financial Statements and Supplementary Data”) during the year ended December 31, 2025 compared to the expenses from the 2024 Synergy Plan for the year ended December 31, 2024.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
interest expense due to a shorter outstanding period of the 2025 Notes (as defined in “Item 7A. Quantitative and Qualitative Disclosure About Market Risk”) in the current period compared to the prior period. Further, there was an increase of $2.4 million from gain on cost method investments. This was partially offset by a decrease in interest income of $8.2 million due to a lower average balance across the Company’s marketable securities, cash and cash equivalents in the current period as compared to the prior period.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
For the year ended December 31, 2025, the decrease in the effective tax rate was primarily due to the release of valuation allowances on certain deferred tax assets of $46.3 million and the impact of the non-taxable bargain purchase gain of $117.7 million in the second quarter of the year ended December 31, 2025, with no comparable event in the prior period.
Read it in 10-K Feb 24, 2026 at sec.gov
RemovedMD&A
We record a provision for litigation settlements when a loss is known or considered probable and the amount can be reasonably estimated and in the case of a favorable settlement, income when realized.
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedMD&A
The $39.7 million or 32.0% increase in research and development expenses shows our continued investment in product development. This increase was primarily driven by increased personnel-related expenses of $24.0 million due to increased headcount and $12.6 of IPR&D expense recorded in the current period from an acquisition.
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedMD&A
The increase of $337.6 million or 52.5% in selling, general and administrative expenses was primarily driven by increases to personnel-related expenses of $251.1 million due to increased headcount primarily from the NuVasive Merger, as well as increases to professional fees of $23.8 million, consulting and outside service expenses of $13.6 million, and rent expenses of $14.3 million.
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedMD&A
A discussion of our Results of Operations for the year ended December 31, 2023 can be found in “Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations: Results of Operations; Year Ended December 31, 2023 Compared to the Year Ended December 31, 2022.” on our Form 10-K filed on February 20, 2024.
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedMD&A
In connection with the NuVasive Merger, the Company acquired additional obligations and commitments, including, but not limited to (i) the 2025 Notes, with a principal balance of $450.0 million, (ii) contingent consideration arrangements associated with certain historical NuVasive acquisitions, and (iii) operating lease and finance lease obligations. Refer to the Notes to the consolidated financial statements for further description of our 2025 Notes (Note 11), contingent consideration arrangements (Notes 6 and 15), and lease obligations (Note 17).
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedMD&A
(2) In connection with certain acquisitions completed in 2011 through 2024, we have certain contingent consideration obligations payable to the sellers in these transactions upon the achievement of certain regulatory and sales milestones. For further information, see Notes 3, and 6 to the consolidated financial statements in “Part II; Item 8. Financial Statements and Supplementary Data.”
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedMD&A
A discussion of our cash flows for the year ended December 31, 2023 can be found in “Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations: Results of Operations; Cash Flows.” On our Form 10-K filed on February 20, 2024.
Read it in 10-K Feb 20, 2025 at sec.gov
RewordedMD&A
The higher cash used in investing activities for the year ended December 31, 2024 2025 was primarily due primarily to decreases an increased outflow of $234.9 million in marketable securities net inflows acquisition of $720.3 million as we manage our liquidity, as well as increased businesses and an increase in purchases of property and equipment of $37.2 million primarily driven $49.3 million, partially offset by increased production resulting from the NuVasive Merger. sales of marketable securities of $103.8 million.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
(“Merger Sub”), (“Nevro”) and Palmer Merger Sub, Inc., a wholly owned subsidiary of the Company, Company (“Palmer Merger Sub”), Palmer Merger Sub merged with and into NuVasive, Nevro (the “Nevro Merger” and, together with the NuVasive Merger, the “NuVasive and Nevro Mergers”), with Nevro surviving as a wholly owned subsidiary of the Company (the “NuVasive Merger”). Company.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
The higher net cash provided by operating activities for the year ended December 31, 2024 2025 was primarily the result of higher net income after adjusting out non-cash add-backs of $434.9 million, favorable changes in deferred income taxes of $144.5 million and non-cash expenses, primarily due to the NuVasive Merger. favorable changes in accounts receivable of $25.9 million.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
The lower net cash used in financing activities for the year ended December 31, 2024 2025 was primarily the result of decreased the repayment of the 2025 Notes for $450.0 million and increased repurchases of Class A Common common stock of $139.8 $214.7 million, and higher proceeds from the exercise of stock options of $98.0 million partially offset by increased decreased payments of business acquisition-related liabilities of $37.6 $30.0 million.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Our cost of sales consists primarily of costs from our in-house manufacturing, costs of products purchased from third-party suppliers, excess and obsolete inventory charges, depreciation of surgical instruments and cases, royalties, shipping, inspection and related costs incurred in making our products available for sale or use.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Regionally, the increase was driven by From a geographic standpoint, sales growth in the Europe and Middle East region increased by $116.9 $49.9 million, the Latin America region by $26.8 million and sales in the Asia Pacific region increased by $87.2 $4.6 million.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Domestic enabling technology Further, there was a decrease in domestic Enabling Technology sales increased by $36.2 of $17.3 million compared to the same period in the prior year, primarily driven by higher lower unit placement.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Amortization of intangibles increased decreased by $68.3 million $1.2 million, or 133.9% 1.0%, for the year ended December 31, 2024 2025 compared to the year ended December 31, 2023, due to the impact of the intangibles acquired from the NuVasive Merger. 2024.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Year Ended December 31, Change (In thousands, except percentages) 2025 2024 2023 $ % Amortization of intangibles Bargain purchase gain $ 119,373 117,704 $ 51,032 $ 68,341 133.9% 117,704 100.0% Percentage of net sales 4.7% 3.3% 4.0 % —%
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Year Ended December 31, Change (In thousands, except percentages) 2025 2024 2023 $ % Acquisition-related costs Other income/(expense), net $ 29,623 7,548 $ 68,274 (45,269) $ (38,651) -56.6% 52,817 (116.7 Percentage of net sales 1.2% 4.4% 0.3 % (1.8
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
From a product standpoint, the increase was mainly due to musculoskeletal solutions primarily driven by Nevro sales increases of $231.3 million, primarily due to spine products. $39.4 million.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
We may also request Swingline Loans (as defined in the September 2023 Credit Agreement) at either the Base Rate or the Daily Term SOFR Rate. Rate (each as defined in the September 2023 Credit Agreement).
Read it in 10-K Feb 24, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/GMED/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.